myeloma – APBN New Site

Antengene Announces XPOVIO® Regulatory Approval in Taiwan for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Diffuse Large B-Cell Lymphoma

November 24, 2022 . Inside Industry . Vol 26 No 11 & 12

XPOVIO® is the first and only exportin 1 (XPO1) inhibitor approved in Taiwan. Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to...

Proteona Awards Grant Funding for Multiple Myeloma Clinical Projects

June 16, 2021 . Inside Industry

The grant awards the receipient $100,000 for projects focused on multiple myeloma aiming to improve treatment outcomes. Proteona, a single-cell precision medicine company, today announced awards from...

Immunotherapy Trials Show Positive Results Against Blood Disease

May 8, 2019 . Eye on China

CAR T cell therapy given to patients found 88 per cent positive. A domestically developed immunotherapy has shown positive results in patients with relapsed or refractory multiple myeloma, a serious...